Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ERYTECH Pharma S.A. (ERYP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1000-0.0700 (-5.98%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.1700
Open1.1900
Bid1.0100 x 2900
Ask1.1500 x 1200
Day's Range1.1000 - 1.1900
52 Week Range1.0000 - 9.5000
Volume15,541
Avg. Volume936,001
Market Cap36.517M
Beta (5Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-1.8520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ERYP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Erytech Pharma S.A.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more
Advertisement
Advertisement